SGMO Financial Facts
Net loss: -18.97MResearch and development: 17.01M
See Full Income Statement
Accounts receivable: 1.48M
Total stockholders' equity: 143.84M
See Full Balance Sheet
Sangamo Biosciences Inc. (SGMO) Earnings
|
Expand Research on SGMO
| Next EPS Date | 8/11/26 | EPS Growth Rate | +25.0% |
|---|---|---|---|
| Average EPS % Beat Rate | -335.8% | Revenue Growth Rate | -5.7% |
| Average % Move 1-Wk after EPS | -3.7% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/11/26  |
Q226 | N/A | -$0.06 | N/A | N/A | $17.25M | N/A | N/A | N/A | ||
| 5/14/26 | Q126 | -$0.08 | -$0.06 | -$0.02 | $1.4M | $35.43M | N/A |  | | Details | |
| 3/10/26 |
Q425 | N/A | -$0.01 | N/A | N/A | $33.18M | N/A | N/A | N/A | ||
| 2/25/26 |
Q425 | N/A | -$0.01 | N/A | N/A | $33.18M | N/A | N/A | N/A | ||
| 2/26/26 |
Q425 | N/A | -$0.01 | N/A | N/A | $33.18M | N/A | N/A | N/A | ||
| 3/2/26 |
Q425 | N/A | -$0.01 | N/A | N/A | $33.18M | N/A | N/A | N/A | ||
| 3/4/26 |
Q425 | N/A | -$0.01 | N/A | N/A | $33.18M | N/A | N/A | N/A | ||
| 3/6/26 |
Q425 | N/A | -$0.01 | N/A | N/A | $33.18M | N/A | N/A | N/A |
